EA201890187A1 - Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита - Google Patents

Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита

Info

Publication number
EA201890187A1
EA201890187A1 EA201890187A EA201890187A EA201890187A1 EA 201890187 A1 EA201890187 A1 EA 201890187A1 EA 201890187 A EA201890187 A EA 201890187A EA 201890187 A EA201890187 A EA 201890187A EA 201890187 A1 EA201890187 A1 EA 201890187A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vlp
particles
recombinant virus
buck
immunodeficiency
Prior art date
Application number
EA201890187A
Other languages
English (en)
Inventor
Питер Пушко
Ирина Третьякова
Original Assignee
Медиджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиджен, Инк. filed Critical Медиджен, Инк.
Publication of EA201890187A1 publication Critical patent/EA201890187A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/866—Baculoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)

Abstract

В заявке описаны рекомбинантные вирусоподобные частицы (VLP) протеина группового антигена вируса бычьего иммунодефицита белка ("Bgag"), содержащие один или несколько различных типов целевых белков-патогенов. Также описаны композиции, содержащие новые VLP Bgag, и способы изготовления и использования новых VLP Bgag.
EA201890187A 2015-07-02 2016-07-01 Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита EA201890187A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188084P 2015-07-02 2015-07-02
PCT/US2016/040838 WO2017004586A1 (en) 2015-07-02 2016-07-01 Recombinant virus like particles using bovine immunodeficiency virus gag protein

Publications (1)

Publication Number Publication Date
EA201890187A1 true EA201890187A1 (ru) 2018-06-29

Family

ID=57609369

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890187A EA201890187A1 (ru) 2015-07-02 2016-07-01 Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита

Country Status (14)

Country Link
US (2) US11576965B2 (ru)
EP (1) EP3316906A4 (ru)
JP (2) JP6978079B2 (ru)
KR (1) KR20180032586A (ru)
CN (2) CN115927212A (ru)
BR (1) BR112018000037A2 (ru)
CA (1) CA2991213A1 (ru)
EA (1) EA201890187A1 (ru)
HK (1) HK1259067A1 (ru)
MA (1) MA42312A (ru)
MX (1) MX2018000023A (ru)
PE (1) PE20180771A1 (ru)
RU (2) RU2757723C2 (ru)
WO (1) WO2017004586A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890187A1 (ru) * 2015-07-02 2018-06-29 Медиджен, Инк. Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
CN112279900A (zh) * 2020-12-30 2021-01-29 乾元浩生物股份有限公司 H9n2亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用
CN113398259A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864085B2 (en) * 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
EP1576143B1 (en) 2002-05-17 2010-11-24 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US20060088909A1 (en) 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US20100143406A1 (en) 2006-06-30 2010-06-10 Gale Smith Methods of enhancing protein incorporation into virus like particles
US20100047266A1 (en) * 2006-07-27 2010-02-25 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
CA2678966A1 (en) * 2007-02-21 2008-08-28 Novavax, Inc. Chimeric newcastle disease virus vlps
CN105586358B (zh) * 2007-05-29 2020-08-25 克里斯多佛·B·里德 专能细胞群的生产和使用方法
RU2010105858A (ru) * 2007-07-19 2011-08-27 Новавакс, Инк. (Us) Вирусоподобные частицы (vlp) вируса varicella zoster и антигены
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
KR20130108983A (ko) * 2010-05-26 2013-10-07 셀렉타 바이오사이언시즈, 인크. 커플링되지 않은 애주번트를 갖는 나노담체 조성물
US20140004146A1 (en) * 2011-03-17 2014-01-02 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Method for producing virus-like particle by using drosophila cell and applications thereof
WO2015066715A1 (en) * 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
EA201890187A1 (ru) * 2015-07-02 2018-06-29 Медиджен, Инк. Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита

Also Published As

Publication number Publication date
RU2018103757A3 (ru) 2019-12-09
KR20180032586A (ko) 2018-03-30
US20180369364A1 (en) 2018-12-27
PE20180771A1 (es) 2018-05-07
CN108348596A (zh) 2018-07-31
RU2020125098A3 (ru) 2020-12-11
JP2020198893A (ja) 2020-12-17
US20230310579A1 (en) 2023-10-05
BR112018000037A2 (pt) 2018-09-04
JP2018525028A (ja) 2018-09-06
MX2018000023A (es) 2018-08-15
RU2020125098A (ru) 2020-09-04
EP3316906A4 (en) 2019-01-02
MA42312A (fr) 2018-05-09
CN115927212A (zh) 2023-04-07
CA2991213A1 (en) 2017-01-05
RU2734118C2 (ru) 2020-10-13
US11576965B2 (en) 2023-02-14
JP6978079B2 (ja) 2021-12-08
EP3316906A1 (en) 2018-05-09
RU2018103757A (ru) 2019-08-05
CN108348596B (zh) 2022-08-23
WO2017004586A1 (en) 2017-01-05
HK1259067A1 (zh) 2019-11-22
RU2757723C2 (ru) 2021-10-21

Similar Documents

Publication Publication Date Title
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
EA202090149A1 (ru) Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
PE20171133A1 (es) Particulas tipo virus modificadas de cmv
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
EA201990017A1 (ru) Антитела к миостатину и способы их применения
WO2014134561A3 (en) Quantification of vaccine compositions
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
EA201890527A1 (ru) Терапевтические вакцины против hpv18
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
MX2017008096A (es) Pestivirus.
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
MX2017003117A (es) Particula tipo virus de flavivirus.
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение